

Rodrigo Machado-Vieira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4708033/publications.pdf>

Version: 2024-02-01

193
papers

12,174
citations

25423

59
h-index

36203

101
g-index

204
all docs

204
docs citations

204
times ranked

14019
citing authors

#	ARTICLE	IF	CITATIONS
1	What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group. <i>Human Brain Mapping</i> , 2022, 43, 56-82.	1.9	67
2	Magnetic Resonance Spectroscopy in Bipolar Disorder. , 2022, , 95-113.		2
3	Intracellular signaling cascades in bipolar disorder. , 2022, , 331-347.		0
4	The role of lithium treatment on comorbid anxiety symptoms in patients with bipolar depression. <i>Journal of Affective Disorders</i> , 2022, 308, 71-75.	2.0	4
5	Lithium increases cortical and subcortical volumes in subjects with bipolar disorder. <i>Psychiatry Research - Neuroimaging</i> , 2022, 324, 111494.	0.9	2
6	Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2022, 27, 3658-3669.	4.1	12
7	The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. <i>Molecular Psychiatry</i> , 2021, 26, 4085-4095.	4.1	48
8	Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group. <i>Molecular Psychiatry</i> , 2021, 26, 5124-5139.	4.1	136
9	Cognitive outcomes of the bipolar depression electrical treatment trial (BETTER): a randomized, double-blind, sham-controlled study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 93-100.	1.8	5
10	Imaging Glutamatergic and GABAergic Abnormalities in Mood Disorders. , 2021, , 105-120.		0
11	Pharmacogenomics of Lithium Response in Bipolar Disorder. <i>Pharmaceuticals</i> , 2021, 14, 287.	1.7	7
12	Inflammatory signaling mechanisms in bipolar disorder. <i>Journal of Biomedical Science</i> , 2021, 28, 45.	2.6	50
13	Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 462-464.	0.9	5
14	Analysis of COVID-19 Infection and Mortality Among Patients With Psychiatric Disorders, 2020. <i>JAMA Network Open</i> , 2021, 4, e2134969.	2.8	27
15	Mood Stabilizers. , 2021, , 1004-1010.		0
16	Using structural MRI to identify bipolar disorders – 13 site machine learning study in 3020 individuals from the ENIGMA Bipolar Disorders Working Group. <i>Molecular Psychiatry</i> , 2020, 25, 2130-2143.	4.1	127
17	Symptom trajectories in the months before and after a suicide attempt in individuals with bipolar disorder: A STEP-BD study. <i>Bipolar Disorders</i> , 2020, 22, 245-254.	1.1	7
18	Intracellular Signaling Cascades in Bipolar Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 48, 101-132.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Biological Targets Underlying the Antisuicidal Effects of Lithium. <i>Current Behavioral Neuroscience Reports</i> , 2020, 7, 165-174.	0.6	0
20	A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 417-425.	1.0	42
21	Psychotic and affective symptoms of early-onset bipolar disorder: an observational study of patients in first manic episode. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 168-174.	0.9	6
22	A Longitudinal MRI-study of the Effects of Lithium on Cortical Thickness and Brain Volume and its association with Clinical Response in Bipolar Disorder. <i>Journal of Affective Disorders</i> , 2019, 254, 139.	2.0	0
23	Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 985-991.	1.1	19
24	Novel Therapeutics in Bipolar Disorder. <i>Current Treatment Options in Psychiatry</i> , 2018, 5, 162-181.	0.7	1
25	Parsing the heterogeneity of depression: An exploratory factor analysis across commonly used depression rating scales. <i>Journal of Affective Disorders</i> , 2018, 231, 51-57.	2.0	62
26	Lithium, Stress, and Resilience in Bipolar Disorder: Deciphering this key homeostatic synaptic plasticity regulator. <i>Journal of Affective Disorders</i> , 2018, 233, 92-99.	2.0	55
27	Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression. <i>JAMA Psychiatry</i> , 2018, 75, 158.	6.0	98
28	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , 2018, 8, 280.	2.4	26
29	Characterizing the course of suicidal ideation response to ketamine. <i>Journal of Affective Disorders</i> , 2018, 241, 86-93.	2.0	44
30	Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A 1H-MRS study. <i>Journal of Affective Disorders</i> , 2018, 241, 192-199.	2.0	18
31	Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. <i>Current Neuropharmacology</i> , 2017, 15, 57-70.	1.4	78
32	New targets for rapid antidepressant action. <i>Progress in Neurobiology</i> , 2017, 152, 21-37.	2.8	118
33	The role of adipokines in the rapid antidepressant effects of ketamine. <i>Molecular Psychiatry</i> , 2017, 22, 127-133.	4.1	75
34	The relationship between genetic risk variants with brain structure and function in bipolar disorder: A systematic review of genetic-neuroimaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 79, 87-109.	2.9	20
35	Increased Brain Lactate During Depressive Episodes and Reversal Effects by Lithium Monotherapy in Drug-Naive Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 40-45.	0.7	64
36	A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 355-358.	0.7	28

#	ARTICLE	IF	CITATIONS
37	Convergent lines of evidence support the role of uric acid levels as a potential biomarker in bipolar disorder. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 107-108.	1.5	12
38	The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. <i>Journal of Psychopharmacology</i> , 2017, 31, 1570-1577.	2.0	17
39	416. The KET-MOA Study: New Findings into the Neurobiology of the Response/non-Response, and Relapse Processes. <i>Biological Psychiatry</i> , 2017, 81, S170.	0.7	0
40	Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 153-166.	1.3	24
41	Genetic Studies on the Tripartite Glutamate Synapse in the Pathophysiology and Therapeutics of Mood Disorders. <i>Neuropsychopharmacology</i> , 2017, 42, 787-800.	2.8	37
42	Increased Activity or Energy as a Primary Criterion for the Diagnosis of Bipolar Mania in DSM-5: Findings From the STEP-BD Study. <i>American Journal of Psychiatry</i> , 2017, 174, 70-76.	4.0	27
43	Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. <i>Journal of Psychiatric Research</i> , 2017, 84, 113-118.	1.5	66
44	Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1068-1074.	1.1	55
45	Plasma Levels of Tumor Necrosis Factor Superfamily Molecules Are Increased in Bipolar Disorder. <i>Clinical Psychopharmacology and Neuroscience</i> , 2017, 15, 269-275.	0.9	17
46	Novel therapeutic targets for bipolar disorder. , 2017, , .		0
47	Lower brain-derived neurotrophic factor levels associated with worsening fatigue in prostate cancer patients during repeated stress from radiation therapy. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 1-7.	1.3	20
48	Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study. <i>Bipolar Disorders</i> , 2016, 18, 363-372.	1.1	40
49	A Selective Association between Central and Peripheral Lithium Levels in Remitters in Bipolar Depression: A ⁷ Li Magnetic Resonance Spectroscopy Study. <i>Acta Psychiatrica Scandinavica</i> , 2016, 133, 214-220.	2.2	23
50	Evidence for increased motor cortical facilitation and decreased inhibition in atypical depression. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 172-182.	2.2	19
51	GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput. <i>Bipolar Disorders</i> , 2016, 18, 702-705.	1.1	16
52	Bias in emerging biomarkers for bipolar disorder. <i>Psychological Medicine</i> , 2016, 46, 2287-2297.	2.7	50
53	Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. <i>Bipolar Disorders</i> , 2016, 18, 63-70.	1.1	32
54	Update on bipolar disorder biomarker candidates. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1209-1220.	1.5	38

#	ARTICLE	IF	CITATIONS
55	Familial aggregation and heritability of the melancholic and atypical subtypes of depression. <i>Journal of Affective Disorders</i> , 2016, 204, 241-246.	2.0	21
56	A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression. <i>Psychopharmacology</i> , 2016, 233, 1119-1130.	1.5	59
57	An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. <i>Journal of Affective Disorders</i> , 2016, 194, 115-119.	2.0	35
58	Antidepressant Efficacy of Adjunctive Aerobic Activity and Associated Biomarkers in Major Depression: A 4-Week, Randomized, Single-Blind, Controlled Clinical Trial. <i>PLoS ONE</i> , 2016, 11, e0154195.	1.1	40
59	Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes. <i>Current Pharmaceutical Design</i> , 2016, 22, 6087-6106.	0.9	77
60	Potential Novel Treatments in Bipolar Depression. <i>Milestones in Drug Therapy</i> , 2016, , 259-285.	0.1	0
61	Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies. <i>BMC Medicine</i> , 2015, 13, 289.	2.3	233
62	Clinical and Biochemical Manifestations of Depression: Relation to the Neurobiology of Stress. <i>Neural Plasticity</i> , 2015, 2015, 1-11.	1.0	160
63	Long-term NMDAR antagonism correlates reduced astrocytic glutamate uptake with anxiety-like phenotype. <i>Frontiers in Cellular Neuroscience</i> , 2015, 09, 219.	1.8	16
64	Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics. <i>Current Neuropharmacology</i> , 2015, 13, 616-635.	1.4	36
65	Translational Research in Bipolar Disorders. <i>Neural Plasticity</i> , 2015, 2015, 1-3.	1.0	2
66	The Bipolar Depression Electrical Treatment Trial (BETTER): Design, Rationale, and Objectives of a Randomized, Sham-Controlled Trial and Data from the Pilot Study Phase. <i>Neural Plasticity</i> , 2015, 2015, 1-10.	1.0	27
67	Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. <i>Neural Plasticity</i> , 2015, 2015, 1-7.	1.0	17
68	Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide. <i>Biological Psychiatry</i> , 2015, 78, 2-4.	0.7	14
69	Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder. <i>European Neuropsychopharmacology</i> , 2015, 25, 468-473.	0.3	65
70	Anterior cingulate Glutamate's Glutamine cycle metabolites are altered in euthymic bipolar I disorder. <i>European Neuropsychopharmacology</i> , 2015, 25, 2221-2229.	0.3	71
71	Development of a clinician-administered National Institutes of Health-Brief Fatigue Inventory: A measure of fatigue in the context of depressive disorders. <i>Journal of Psychiatric Research</i> , 2015, 68, 99-105.	1.5	7
72	Prevalence and correlates of major depressive disorder and dysthymia in an eleven-year follow-up " Results from the Finnish Health 2011 Survey. <i>Journal of Affective Disorders</i> , 2015, 173, 73-80.	2.0	67

#	ARTICLE	IF	CITATIONS
73	Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. <i>Human Psychopharmacology</i> , 2015, 30, 52-56.	0.7	26
74	Cognitive Dysfunction in Depression – Pathophysiology and Novel Targets. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 13, 1819-1835.	0.8	82
75	Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial. <i>Journal of Affective Disorders</i> , 2015, 185, 209-213.	2.0	24
76	Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 97-114.	1.1	169
77	BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: A systematic review and meta-analysis. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 114-122.	1.3	44
78	Lithium increases platelet serine-9 phosphorylated GSK-3 ^β levels in drug-free bipolar disorder during depressive episodes. <i>Journal of Psychiatric Research</i> , 2015, 62, 78-83.	1.5	47
79	Bimodal Effect of Lithium Plasma Levels on Hippocampal Glutamate Concentrations in Bipolar II Depression: A Pilot Study. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, .	1.0	18
80	A Longitudinal (6-week) 3T 1H-MRS Study on the Effects of Lithium Treatment on Anterior Cingulate Cortex Metabolites in Bipolar Depression. <i>European Neuropsychopharmacology</i> , 2015, 25, 2311-2317.	0.3	50
81	Regulation of leukocyte tricarboxylic acid cycle in drug-naïve Bipolar Disorder. <i>Neuroscience Letters</i> , 2015, 605, 65-68.	1.0	12
82	Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 57, 117-131.	2.5	89
83	Shank3 as a potential biomarker of antidepressant response to ketamine and its neural correlates in bipolar depression. <i>Journal of Affective Disorders</i> , 2015, 172, 307-311.	2.0	27
84	Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): An exploratory analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 91-96.	2.5	32
85	D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. <i>Psychopharmacology</i> , 2015, 232, 399-409.	1.5	62
86	Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. <i>Psychopharmacology</i> , 2015, 232, 245-250.	1.5	51
87	Reduced activities of phospholipases A ₂ in platelets of drug-naïve bipolar disorder patients. <i>Bipolar Disorders</i> , 2015, 17, 97-101.	1.1	10
88	Elevated neurotrophin-3 and neurotrophin 4/5 levels in unmedicated bipolar depression and the effects of lithium. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 243-246.	2.5	27
89	Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 167-170.	1.8	10
90	Translating Biomarkers and Biomolecular Treatments to Clinical Practice. , 2015, , 149-168.		2

#	ARTICLE	IF	CITATIONS
91	Predictors of treatment response in major depressive disorder. , 2015, , 53-60.		0
92	Novel therapeutic targets for major depressive disorder. , 2015, , 135-146.		0
93	Biomarkers in mood disorders research: developing new and improved therapeutics. Revista De Psiquiatria Clinica, 2014, 41, 131-134.	0.6	11
94	The Next Generation of Clinical Studies with Antidepressants in Bipolar Disorder. Frontiers in Psychiatry, 2014, 5, 27.	1.3	0
95	Lithium safety and tolerability in mood disorders: a critical review. Revista De Psiquiatria Clinica, 2014, 41, 9-14.	0.6	7
96	Association study between COMT 158Met and creativity scores in bipolar disorder and healthy controls. Revista De Psiquiatria Clinica, 2014, 41, 29-33.	0.6	0
97	Decreased plasma neurotrophin-4/5 levels in bipolar disorder patients in mania. Revista Brasileira De Psiquiatria, 2014, 36, 340-343.	0.9	14
98	BDNF blood levels after electroconvulsive therapy in patients with mood disorders: A systematic review and meta-analysis. World Journal of Biological Psychiatry, 2014, 15, 411-418.	1.3	89
99	Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: Developing treatments using an integrated translational approach. World Journal of Biological Psychiatry, 2014, 15, 84-95.	1.3	52
100	Reduced Cerebrospinal Fluid Levels of Brain-Derived Neurotrophic Factor Is Associated With Cognitive Impairment in Late-Life Major Depression. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2014, 69, 845-851.	2.4	54
101	Baseline Vitamin B12 and Folate Levels Do Not Predict Improvement in Depression After a Single Infusion of Ketamine. Pharmacopsychiatry, 2014, 47, 141-144.	1.7	14
102	Neuroanatomical Classification in a Population-Based Sample of Psychotic Major Depression and Bipolar I Disorder with 1 Year of Diagnostic Stability. BioMed Research International, 2014, 2014, 1-9.	0.9	44
103	Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opinion on Therapeutic Targets, 2014, 18, 1131-1147.	1.5	44
104	Cytokines in Bipolar Disorder: Paving the Way for Neuroprogression. Neural Plasticity, 2014, 2014, 1-9.	1.0	112
105	The Immunology of Bipolar Disorder. NeuroImmunoModulation, 2014, 21, 117-122.	0.9	117
106	Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology, 2014, 231, 1315-1323.	1.5	52
107	DEVELOPING BIOMARKERS IN MOOD DISORDERS RESEARCH THROUGH THE USE OF RAPID-ACTING ANTIDEPRESSANTS. Depression and Anxiety, 2014, 31, 297-307.	2.0	43
108	Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. Journal of Psychiatric Research, 2014, 50, 36-41.	1.5	135

#	ARTICLE	IF	CITATIONS
109	Lithium increases nitric oxide levels in subjects with bipolar disorder during depressive episodes. <i>Journal of Psychiatric Research</i> , 2014, 55, 96-100.	1.5	24
110	Adipokines as emerging depression biomarkers: A systematic review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2014, 59, 28-37.	1.5	98
111	BDNF plasma levels after antidepressant treatment with sertraline and transcranial direct current stimulation: Results from a factorial, randomized, sham-controlled trial. <i>European Neuropsychopharmacology</i> , 2014, 24, 1144-1151.	0.3	42
112	Leukocyte mitochondrial DNA copy number in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 48, 32-35.	2.5	57
113	Leukocyte telomerase activity and antidepressant efficacy in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2014, 24, 1139-1143.	0.3	16
114	Lithium Decreases Plasma Adiponectin Levels in Bipolar Depression. <i>Neuroscience Letters</i> , 2014, 564, 111-114.	1.0	34
115	Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1205-1208.	0.8	19
116	Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e417-e423.	1.1	120
117	Novel biomarkers for bipolar disorder. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 147-159.	1.6	26
118	Bcl-2 rs956572 Polymorphism is Associated with Increased Anterior Cingulate Cortical Glutamate in Euthymic Bipolar I Disorder. <i>Neuropsychopharmacology</i> , 2013, 38, 468-475.	2.8	65
119	Reduced Serum Nerve Growth Factor in Patients With Late-Life Depression. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 493-496.	0.6	65
120	Early improvement with lithium in classic mania and its association with later response. <i>Journal of Affective Disorders</i> , 2013, 144, 160-164.	2.0	22
121	The <i>CACNA1C</i> risk allele selectively impacts on executive function in bipolar type I disorder. <i>Acta Psychiatrica Scandinavica</i> , 2013, 128, 362-369.	2.2	34
122	Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 493.	1.0	105
123	Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1505-1512.	1.0	73
124	Gender effects of the COMT Val158Met genotype on verbal fluency in healthy adults. <i>Molecular Medicine Reports</i> , 2013, 8, 837-844.	1.1	18
125	Association of the COMT Met158 allele with trait impulsivity in healthy young adults. <i>Molecular Medicine Reports</i> , 2013, 7, 1067-1072.	1.1	46
126	The impact of limbic system morphology on facial emotion recognition in bipolar I disorder and healthy controls. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 743.	1.0	6

#	ARTICLE	IF	CITATIONS
127	Next-generation strategies in animal model research to translate preclinical discoveries into better treatments for circuit-centered psychiatric dimensions. <i>Revista Brasileira De Psiquiatria</i> , 2013, 35, S75-S76.	0.9	1
128	Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: Pathophysiological and therapeutic implications (Review). <i>Molecular Medicine Reports</i> , 2012, 6, 915-22.	1.1	13
129	An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. <i>International Journal of Neuropsychopharmacology</i> , 2012, 15, 1063-1072.	1.0	77
130	Purinergic System in the Treatment of Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 735-736.	0.7	31
131	Early improvement of psychotic symptoms with lithium monotherapy as a predictor of later response in mania. <i>Journal of Psychiatric Research</i> , 2012, 46, 1564-1568.	1.5	14
132	Tracking the impact of translational research in psychiatry: state of the art and perspectives. <i>Journal of Translational Medicine</i> , 2012, 10, 175.	1.8	27
133	Translating neurotrophic and cellular plasticity: from pathophysiology to improved therapeutics for bipolar disorder. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 332-341.	2.2	57
134	Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. <i>Acta Psychiatrica Scandinavica</i> , 2012, 126, 315-331.	2.2	111
135	Does Lithium Prevent Alzheimer's Disease?. <i>Drugs and Aging</i> , 2012, 29, 335-342.	1.3	122
136	The impact of the CACNA1C risk allele on limbic structures and facial emotions recognition in bipolar disorder subjects and healthy controls. <i>Journal of Affective Disorders</i> , 2012, 141, 94-101.	2.0	58
137	COMT Met (158) modulates facial emotion recognition in bipolar I disorder mood episodes. <i>Journal of Affective Disorders</i> , 2012, 136, 370-376.	2.0	27
138	Plasma cortisol in first episode drug-naïve mania: Differential levels in euphoric versus irritable mood. <i>Journal of Affective Disorders</i> , 2012, 138, 149-152.	2.0	30
139	Does BDNF genotype influence creative output in bipolar I manic patients?. <i>Journal of Affective Disorders</i> , 2012, 139, 181-186.	2.0	16
140	Novel glutamatergic agents for major depressive disorder and bipolar disorder. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 100, 678-687.	1.3	77
141	COMT polymorphisms as predictors of cognitive dysfunction during manic and mixed episodes in bipolar I disorder. <i>Bipolar Disorders</i> , 2012, 14, 554-564.	1.1	46
142	Reduced Serum Nerve Growth Factor in Patients With Late-Life Depression. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	0.6	2
143	The Bcl-2 Gene Polymorphism rs956572AA Increases Inositol 1,4,5-Trisphosphate Receptor-Mediated Endoplasmic Reticulum Calcium Release in Subjects with Bipolar Disorder. <i>Biological Psychiatry</i> , 2011, 69, 344-352.	0.7	65
144	Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study. <i>Brain Research Bulletin</i> , 2011, 86, 129-133.	1.4	38

#	ARTICLE	IF	CITATIONS
145	Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: A preliminary 4-week study. <i>Neuroscience Letters</i> , 2011, 494, 54-56.	1.0	125
146	Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1155-1159.	2.5	165
147	Current pharmacological approaches and perspectives in the treatment of geriatric mood disorders. <i>Current Opinion in Psychiatry</i> , 2011, 24, 473-477.	3.1	7
148	Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. <i>Brain Research</i> , 2011, 1403, 19-27.	1.1	27
149	Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene-Environment Interactions. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 699-704.	1.9	91
150	Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. <i>Depression and Anxiety</i> , 2011, 28, 267-281.	2.0	23
151	Effects of lithium on oxidative stress parameters in healthy subjects. <i>Molecular Medicine Reports</i> , 2011, 5, 680-2.	1.1	94
152	Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. <i>Neurobiology of Disease</i> , 2010, 40, 608-621.	2.1	77
153	New Therapeutic Targets for Mood Disorders. <i>Scientific World Journal, The</i> , 2010, 10, 713-726.	0.8	50
154	The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. <i>Pharmaceuticals</i> , 2010, 3, 19-41.	1.7	168
155	Novel Insights into Lithium's Mechanism of Action: Neurotrophic and Neuroprotective Effects. <i>Neuropsychobiology</i> , 2010, 62, 50-60.	0.9	183
156	A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression. <i>Archives of General Psychiatry</i> , 2010, 67, 793.	13.8	848
157	A kinesin signaling complex mediates the ability of GSK-3 β to affect mood-associated behaviors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11573-11578.	3.3	110
158	Synaptic Plasticity in the Pathophysiology and Treatment of Bipolar Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 5, 167-185.	0.8	11
159	Glutamatergic Modulators: The Future of Treating Mood Disorders?. <i>Harvard Review of Psychiatry</i> , 2010, 18, 293-303.	0.9	203
160	Potential Novel Therapeutics for Bipolar Disorders. <i>Current Topics in Behavioral Neurosciences</i> , 2010, 5, 303-329.	0.8	4
161	Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine. <i>Neuropsychopharmacology</i> , 2010, 35, 1415-1422.	2.8	195
162	Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 819-821.	2.5	76

#	ARTICLE	IF	CITATIONS
163	Rapid Resolution of Suicidal Ideation After a Single Infusion of an N-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1605-1611.	1.1	487
164	The Neurobiology of the Switch Process in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1488-1501.	1.1	179
165	Neuroprotective Agents in Mood Disorders: Pathophysiological and Therapeutic Implications. , 2010, , 417-449.		0
166	A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 561.	1.0	267
167	The Role of the Tripartite Glutamatergic Synapse in the Pathophysiology and Therapeutics of Mood Disorders. <i>Neuroscientist</i> , 2009, 15, 525-539.	2.6	157
168	Dynamic regulation of mitochondrial function by glucocorticoids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3543-3548.	3.3	392
169	Ketamine and the next generation of antidepressants with a rapid onset of action. , 2009, 123, 143-150.		229
170	The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. <i>Bipolar Disorders</i> , 2009, 11, 92-109.	1.1	289
171	Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of Mania. <i>Neuropharmacology</i> , 2009, 56, 47-55.	2.0	90
172	Bipolar I and II disorder residual symptoms: Oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 94-99.	2.5	52
173	Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders. <i>Current Pharmaceutical Design</i> , 2009, 15, 1595-1611.	0.9	107
174	Brain-Derived Neurotrophic Factor and Initial Antidepressant Response to an N-Methyl-D-Aspartate Antagonist. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1662-1666.	1.1	131
175	The Role of Hippocampal GluR1 and GluR2 Receptors in Manic-Like Behavior. <i>Journal of Neuroscience</i> , 2008, 28, 68-79.	1.7	98
176	Rapid Onset of Antidepressant Action. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 946-958.	1.1	166
177	A Double-Blind, Randomized, Placebo-Controlled 4-Week Study on the Efficacy and Safety of the Purinergic Agents Allopurinol and Dipyridamole Adjunctive to Lithium in Acute Bipolar Mania. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1237-1245.	1.1	111
178	Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects. <i>Neuroscience Letters</i> , 2007, 421, 33-36.	1.0	281
179	Decreased Plasma Brain Derived Neurotrophic Factor Levels in Unmedicated Bipolar Patients During Manic Episode. <i>Biological Psychiatry</i> , 2007, 61, 142-144.	0.7	187
180	The Portuguese version of the Clinical Global Impression - Schizophrenia Scale: validation study. <i>Revista Brasileira De Psiquiatria</i> , 2007, 29, 246-249.	0.9	14

#	ARTICLE	IF	CITATIONS
181	Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 519-526.	0.5	45
182	Emerging novel treatments for severe mood disorders involving cellular plasticity cascades. <i>Current Psychosis & Therapeutics Reports</i> , 2006, 4, 181-190.	0.1	2
183	As bases neurobiológicas do transtorno bipolar. <i>Revista De Psiquiatria Clinica</i> , 2005, 32, 28-33.	0.6	4
184	A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. <i>Human Psychopharmacology</i> , 2005, 20, 133-139.	0.7	24
185	Perspectives for the development of animal models of bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 209-224.	2.5	140
186	Increased cerebrospinal fluid levels of S100B protein in rat model of mania induced by ouabain. <i>Life Sciences</i> , 2004, 76, 805-811.	2.0	30
187	Transtorno de estresse pós-traumático e transtorno de humor bipolar. <i>Revista Brasileira De Psiquiatria</i> , 2003, 25, 55-61.	0.9	3
188	Neurobiologia do transtorno de humor bipolar e tomada de decisão na abordagem psicofarmacológica. <i>Revista De Psiquiatria Do Rio Grande Do Sul</i> , 2003, 25, 88-105.	0.3	2
189	Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. <i>European Neuropsychopharmacology</i> , 2002, 12, 269-272.	0.3	61
190	Purinergic dysfunction in mania: an integrative model. <i>Medical Hypotheses</i> , 2002, 58, 297-304.	0.8	79
191	Mania Associated with an Energy Drink: The Possible Role of Caffeine, Taurine, and Inositol. <i>Canadian Journal of Psychiatry</i> , 2001, 46, 454-455.	0.9	48
192	Therapeutic Efficacy of Allopurinol in Mania Associated With Hyperuricemia. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 621-622.	0.7	44
193	Scientific advances in psychiatry. <i>Revista Debates Em Psiquiatria</i> , 0, Ano 6, 28-33.	0.3	0